Navigation Links
Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction

MISSISSAUGA, Ontario, May 2, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today congratulated Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that Cephalon has agreed to be acquired by Teva.  In response to the news, Valeant has withdrawn its consent solicitation.

"We believe that this announcement is positive news for Cephalon stockholders and we are pleased that Teva has paid what we believe is a very full value for the company and as a result, have withdrawn our consent solicitation," stated J. Michael Pearson, chairman and chief executive officer.  "As Cephalon stockholders ourselves with over a million shares owned, we will benefit from this transaction without participating further in the process.  We will remain disciplined on our M&A strategy and will look to deploy our freed-up capital on other opportunities to create value for our shareholders."

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's expectation to benefit from the proposed acquisition of Cephalon by Teva and opportunities to create value for Valeant shareholders. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little    
Valeant Pharmaceuticals International, Inc.  

Renee E. Soto
Sard Verbinnen & Co.

Cassandra Bujarski
Sard Verbinnen & Co.



SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
2. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
3. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
4. Regulatory Update - GSK and Valeant Respond to FDA on ezogabine
5. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
6. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
7. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
8. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
9. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
10. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
11. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... die sich einer Kolonoskopie im Rahmen eines ... unterziehen. Die NOCT-Studie bewertete auch die Compliance, ... --> ® ) an erwachsenen Patienten ... eines Screenings, einer beobachtenden oder einer diagnostischen ...
(Date:10/9/2015)... , October 9, 2015 ... (OTCQB: CNBX) has announced its execution of an Intellectual Property ... Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, ... --> --> These ... of the Company, whereby the Research and Development components ...
(Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
Breaking Medicine Technology:
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Each ... internships at the pre-eminent organization in global health: the World Health Organization (WHO). ... health disparities. These internships are a mechanism for WHO to help build public ...
(Date:10/9/2015)... ... October 09, 2015 , ... "My spouse and I rely on ... leaned against something," said an inventor from Buffalo, N.Y. "This is not only frustrating ... , The CANE REST enables a user to keep a cane upright while it’s ...
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic Arts ... developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. , ... Heels girls team head coach and executive director, said. “It's a stepping stone into ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance has ... community improvement initiative that involves working with a series of local charities throughout ... Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... of Innovations with Ed Begley Jr., airing 1st QT 2016 via the Discovery ... audiences on MMJ Phytotech Limited (MMJ) – a global leader in the field ...
Breaking Medicine News(10 mins):
... aiding certain patients with the blood cancer , , WEDNESDAY, ... of the once-banned drug thalidomide for patients with myeloma ... as it is to science: Don,t judge results too ... therapy regimens increased the odds of a complete remission, ...
... Counseling for All Combat Veterans, WASHINGTON, July 9 ... in 39 additional,communities across the country where the Department ... 2009., "Community-based Vet Centers -- already in all ... health program," said Dr. James B. Peake,Secretary of Veterans ...
... conditions cause significant decrease in body,s ability to repair ... News) -- Diabetes and being over- or underweight can ... the conclusion of two reports to be presented July ... of Human Reproduction & Embryology, in Barcelona, Spain. , ...
... Inc.,(NYSE and SWX: ZMH) announced today its second quarter ... over the Internet on,Thursday, July 24, 2008, at 8:00 ... will be made available at 7:00 a.m. the,morning of ... be accessed via Zimmer,s Investor Relations,website at ...
... the elderly and people without health insurance especially vulnerable, ... Every summer, an estimated 6,200 Americans are hospitalized for ... who were hospitalized died, according to the latest ... Healthcare Research and Quality. , Severe heat exposure, ...
... neighborhoods to advance benefits of selecting Michigan ... July 9 The Associated Food &,Petroleum Dealers (AFPD) ... to make fresh, local produce more readily,available to Metro ... program called "Buy Local, Eat Fresh.", "We have ...
Cached Medicine News:
... effective technology in anesthesia., ,Whether you ... ventilation, the operating theater or as a ... monitoring, the Aliseo product family allows you ... ,With three product models, you have the ...
... performance and value., ,The Aestiva/5 7100 ... the Aestiva/5 anesthesia system (open architecture, integrated ... newest anesthesia ventilation platform - the 7100 ... engineered to allow for ventilation of a ...
... ,The Aestiva/5 offers exceptional capabilities and flexibility, ... therapy., ,The Aestiva/5 with SmartVent offers ... ventilator, saving you the cost of bringing ... Its flexible ergonomic design and intuitive operations ...
... to quality patient care., ,S/5 Anesthesia ... to anesthesia delivery. As part of the ... features, electronically controlled gas delivery and agent ... to create a truly integrated system. The ...
Medicine Products: